Akut Kalp Yetersizliğinde Taburculuk Öncesi ve Sonrası Hasta Yönetimi ve Tedavi Optimizasyonu
Yıl: 2022 Cilt: 50 Sayı: 5 Sayfa Aralığı: 378 - 394 Metin Dili: İngilizce DOI: 10.5543/tkda.2022.22329 İndeks Tarihi: 26-07-2022
Akut Kalp Yetersizliğinde Taburculuk Öncesi ve Sonrası Hasta Yönetimi ve Tedavi Optimizasyonu
Öz: Akut kalp yetersizliği (KY), hızlı müdahale ve erken tedavi başlanması ve yoğunlaştırmasını
gerektiren, mortalite ve tekrar hastaneye yatış oranları yüksek bir klinik tablodur. Ölüm ve tekrar
hastaneye yatış riski taburculuk sonrası erken dönemde, özellikle ilk 3-6 ay içinde en yüksek
düzeyde olup, sonraki dönemde giderek azalır ve bu dönem akut KY sonrası hassas dönem olarak
adlandırılır. Bu nedenle kılavuz temelli optimal medikal tedavi sadece akut KY’nin akut fazı için
değil aynı zamanda taburculuk öncesi ve sonrası dönem içinde oldukça önemlidir. Taburculuk
öncesi dönem; konjesyonun elimine edilmesi, komorbiditeler veya tetikleyici faktörlerin tedavisi
ve taburculuk öncesi oral tedavinin başlanması veya uptitre edilmesi için bir fırsat penceresi
sunar. Taburculuk sonrası erken dönemde, klinik ve laboratuvar sonuçlarına göre tedavinin
ileri optimizasyonunun 30 günlük tekrar hastaneye yatışları azalttığı gösterilmiştir. Ancak klinik
uygulamada genelde klinisyenler akut KY’nin intravenöz medikasyon veya kısa dönem cihaz
tedavisi gerektiren akut fazına odaklanmakta, kısa ve uzun dönem kapsamlı yaklaşımları göz
ardı etmektedir. Bu belge; taburculuk öncesi ve taburculuk sonrası ölüm ve tekrar hastaneye
yatışları azaltmaya yardımcı olan yönetim stratejilerini, KY’de bütünsel yaklaşımlara adaptasyon,
kanıta dayalı tedavi optimizasyonu, kardiyak ve nonkardiyak komorbiditelerin kontrolü, hasta
bakımının düzeltilmesi, monitörizasyonu ve hastalık yönetimi temelinde gözden geçirmektedir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Erişime Açık
- 1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. [CrossRef]
- 2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147 -e239. [CrossRef]
- 3. Ural D, Çavuşoğlu Y, Eren M, et al. Diagnosis and management of acute heart failure. Anatol J Cardiol. 2015;15(11):860-889. [CrossRef]
- 4. Hollenberg SM, Stevenson LW, Ahmad T, et al. ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure. Am J Coll Cardiol. 2019;74:1966-2011.
- 5. Eren M, Zoghi M, Tuncer M, et al. Turkish registry for diagnosis and treatment of acute heart failure: TAKTIK study. Turk Kardiyol Dern Ars. 2016;44(8):637-646. [CrossRef]
- 6. Maggioni AP, Dahlström U, Filippatos G, et al. EURObservational research programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15(7):808-817. [CrossRef]
- 7. Yılmaz MB, Aksakal E, Aksu U, et al. Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: a follow up data for mortality. Anatol J Cardiol. 2020;23(3):160-168. [CrossRef]
- 8. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization of heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116(13):1482-1487. [CrossRef]
- 9. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for HF. J Am Coll Cardiol. 2013;61(4):391-403. [CrossRef]
- 10. Ryan J, Kang S, Dolacky S, Ingrassia J, Ganeshan R. Change in readmissions and follow-up visits as part of a heart failure readmission quality improvement initiative. Am J Med. 2013;126(11):989-994. e1. [CrossRef]
- 11. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure.Am Heart J. 2000;140(6):840-847. [CrossRef]
- 12. Ambrosy AP, Pang PS, Khan S, et al. Clinical course and predictive value of congestion during hospitaliza- tion in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the Everest trial. Eur Heart J. 2013;34(11):835-843. [CrossRef]
- 13. Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110(15):2168-2174. [CrossRef]
- 14. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment ofdecompensated heart failure on renal function and survival. Circulation. 2010;122(3):265-272. [CrossRef]
- 15. O'Connor CM, Miller AB, Blair JE,et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (Everest) program.Am Heart J. 2010;159(5):841-849.e1. [CrossRef]
- 16. Butler J, Braunwald E, Gheorghiade M. Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. JAMA. 2014;312(8):789-790. [CrossRef]
- 17. Maddox TM, Januzzi JL, Allen LA, et al. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol. 2021;77(6):772-810. [CrossRef]
- 18. McMurray JJ, Packer M, Desai AS, et al. Angio- tensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. [CrossRef]
- 19. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decom- pensated heart failure. N Engl J Med. 2019;380(6):539-548. [CrossRef]
- 20. Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/ valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSI- TION study. Eur J Heart Fail. 2019;21(8):998-1007. [CrossRef]
- 21. Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures,devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society Cardiology. Eur J Heart Fail. 2019;21(10):1169-1186. [CrossRef]
- 22. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. [CrossRef]
- 23. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. [CrossRef]
- 24. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR- Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-829. [CrossRef]
- 25. Szarek M, Bhatt DL, Steg PG, et al. Effect of Sotagliflozin on Total Hospitalizations in patients with type 2 diabetes and worsening heart failure: a randomized trial. Ann Intern Med. 2021;174(8):1065- 1072. [CrossRef]
- 26. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883-1893. [CrossRef]
- 27. Jankowska EA, Kirwan BA, Kosiborod M, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J. 2021;42:3011-3020. [CrossRef]
- 28. Williams B, Mancia G, Spiering W, et al. ESC/ESH guidelines fort he management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Eur Heart J. 2018;39:3021-3104.
- 29. Cosentino F, Grant PJ, Aboyans V, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developrd in collaboration with EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiolıgy and European Association fort he study of diabetes. Eur Heart J. 2019;41:255-323.
- 30. Sessa M, Mascolo A, Scavone C, et al. Comparison of long-term clinical implications of beta-blocker in patients with obdtructive airway diseases exposed to beta-blocker with different B1-adrenoceptor selectivity: an Italian population-based cohort study. Front Pharmacol. 2018;9:1212. [CrossRef]
- 31. Sessa M, Mascolo A, Mortensen RN, et al. Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. Eur J Heart Fail. 2018;20(3):548-556. [CrossRef]
- 32. Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive servo-ventilation for central sleep-apnea in systolic heart failure. N Engl J Med. 2015;373(12):1095-1105. [CrossRef]
- 33. Bradley TD, Logan AG, Kimoff RJ, et al. Continous positive airway pressure for central sleep-apnea and heart failure. N Engl J Med. 2005;353:2025-2033.
- 34. Rosano GMC, Moura B, Metra M, et al. Patients profiling in heart failure for tailoring medical therapy: a consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021;23(6):872-881. [CrossRef]
- 35. Filippatos G, Farmakis D, Colet JC, et al. Intravenous ferric carboxymaltose in iron deficient chronic heart failure patients with and without anemia: a subanalysis of FAIR-HF trial. Eur J Heart Fail. 2013;15(11):1267-1276. [CrossRef]
- 36. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J. 2015;36(11):657-668. [CrossRef]
- 37. Jankowska EA, Tkaczyszyn M, Suchocki T, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of controlled trials. Eur J Heart Fail. 2016;18(7):786-795. [CrossRef]
- 38. Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicenter, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895-1904. [CrossRef]
- 39. Arrigo M, Jessup M, Mullens W, et al., Acute heart failure. Nat Rev Dis Primers. 2020;6(1):16. [CrossRef]
- 40. Miro O, Rossello X, Platz E, et al. Risk stratification scores for patients with acute heart failure in the emergency department: a systemic review. Eur Heart J Acute Cardiovasc Care. 2020;5:375-398.
- 41. Flint KM, Allen LA, Pham M, Heidenreich PA. B-type natriuretic peptide predicts 30-day readmission for heart failure but not readmission for other causes. J Am Heart Assoc. 2014;3(3):e000806. [CrossRef]
- 42. Sinnenberg L, Givertz MM. Acute heart failure. Trends Cardiovasc Med. 2020;30(2):104-112. [CrossRef]
- 43. Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiolıgy. Eur J Heart Fail. 2018;20(11):1505- 1535. [CrossRef]
- 44. Rubio-Gracia J, Demissei BG, ter Maaten JM, et al. Prevalence, predictırs and clinical outcome of residual congestion in acute decompansated heart failure. Int J Cardiol. 2018;258:185-191. [CrossRef]
- 45. Mebazaa A, Yılmaz MB, Levy P, et al. Recommendations on prehospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency-Medicine – short version. Eur Heart J. 2015;36(30):1958-1966. [CrossRef]
- 46. Harjola VP, Parissis J, Brunner-La Rocca HP, et al. Comprehensive in-hospital monitoring in acute herat failure: applications for clinical practice and future directions for researsch. A statement from the Acute Heart Failure Committee of Heart failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(7):1081- 1099. [CrossRef]
- 47. Ezekowitz JA, O'Meara E, McDonald MA, et al. 2017 Comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. Can J Cardiol. 2017;33(11):1342- 1433. [CrossRef]
- 48. Aldahl M, Jensen A-SC, Davidsen L, et al. Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J. 2017;38(38):2890-2896. [CrossRef]
- 49. Wei L, Struthers AD, Fahey T, Watson AD, Macdonald TM. Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ. 2010;340:c1768. [CrossRef]
- 50. Zannad F, Rossignol P. Cardiorenal syndrome revisited. Circulation. 2018;138(9):929-944. [CrossRef]
- 51. Serenelli M, Jackson A, Dewan P, et al. Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC Heart Fail. 2020;8(3):188-198. [CrossRef]
- 52. Aldabagh MA, Dey AK, Cesa M, Florante R, Sorensen K, Goldberg Y. Early cardiac rehabilitation for patients With acute decompensated heart failure. Arterioscler Thromb Vasc Biol. 2020;40:A369.
- 53. Warraich HJ, Kitzman DW, Whellan DJ, et al. Physical function, frailty, cognition, depression, and quality of life in hospitalized adults ≥60 years with acute decompensated heart failure with preserved versus reduced eection fraction. Circ Heart Fail. 2018;11(11):e005254. [CrossRef]
- 54. Iwata K, Kitai T, Yoshimura Y, et al. Clinical impact of functional independent measure (FIM) on 180-day readmission and mortality in elderly patients hospitalized with acute decompensated heart failure. Heart Vessels. 2021;36(10): 1536-1541. [CrossRef]
- 55. Doehner W, Ural D, Haeusler KG, et al. Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association. Eur J Heart Fail. 2018;20(2):199-215. [CrossRef]
- 56. Kuehneman T, Saulsbury D, Splett P, Chapman DB. Demonstrating the impact of nutrition intervention in a heart failure program. J Am Diet Assoc. 2002;102(12):1790-1794. [CrossRef]
- 57. Khan MS, Jones DW, Butler J. Salt, no salt, or less salt for patients with heart failure? Am J Med. 2020;133(1):32-38. [CrossRef]
- 58. Daniels D, De Luca LA, Menani JV, Johnson AK. Diverse roles of angiotensin receptor intracellular signaling pathways in the control of water and salt intake. In: Neurobiology of Body Fluid Homeostasis: Transduction and Integration. Boca Raton (FL): CRC. Press/Taylor & Francis; 2014.
- 59. Sakai RR, Ma LY, Zhang DM, McEwen BS, Fluharty SJ. Intracerebral administration of mineralocorticoid receptor antisense oligonucleotides attenuate adrenal steroid-induced salt appetite in rats. Neuroendocrinology. 1996;64(6):425-429. [CrossRef]
- 60. Francis J, Weiss RM, Wei SG, et al. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol Heart Circ Physiol. 2001;281(5):H22 41-H2251. [CrossRef]
- 61. Toth E, Stelfox J, Kaufman S. Cardiac control of salt appetite. Am J Physiol. 1987;252(5 Pt 2):R925-R929. [CrossRef]
- 62. De Gobbi JI, Menani JV, Beltz TG, Johnson RF, Thunhorst RL, Johnson AK. Right atrial stretch alters fore- and hind-brain expression of c-fos and inhibits the rapid onset of salt appetite. J Physiol. 2008;586(15):3719-3729. [CrossRef]
- 63. Cohen LP, Wessler JD, Maurer MS, Hummel SL. Salt taste sensitivity and heart failure outcomes following heart failure hospitalization. Am J Cardiol. 2020;127:58-63. [CrossRef]
- 64. Senturk B, Kaya H, Celik A, et al. Noncompliance with dietary salt restriction and outcomes in chronic heart failure: a propensity score matching analysis from TREAT-HF Registry. Haseki. 2021;59(2):114- 121. [CrossRef]
- 65. Hummel SL, DeFranco AC, Skorcz S, Montoye CK, Koelling TM. Recommendation of low-salt diet and short-term outcomes in heart failure with preserved systolic function. Am J Med. 2009;122(11):1029-1036. [CrossRef]
- 66. Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation. 2018;138(1):80- 98. [CrossRef]
| APA | Çavuşoğlu Y, Altay H, Nalbantgil S, Temizhan A, YILMAZ M (2022). Akut Kalp Yetersizliğinde Taburculuk Öncesi ve Sonrası Hasta Yönetimi ve Tedavi Optimizasyonu. , 378 - 394. 10.5543/tkda.2022.22329 |
| Chicago | Çavuşoğlu Yüksel,Altay Hakan,Nalbantgil Sanem,Temizhan Ahmet,YILMAZ MEHMET BIRHAN Akut Kalp Yetersizliğinde Taburculuk Öncesi ve Sonrası Hasta Yönetimi ve Tedavi Optimizasyonu. (2022): 378 - 394. 10.5543/tkda.2022.22329 |
| MLA | Çavuşoğlu Yüksel,Altay Hakan,Nalbantgil Sanem,Temizhan Ahmet,YILMAZ MEHMET BIRHAN Akut Kalp Yetersizliğinde Taburculuk Öncesi ve Sonrası Hasta Yönetimi ve Tedavi Optimizasyonu. , 2022, ss.378 - 394. 10.5543/tkda.2022.22329 |
| AMA | Çavuşoğlu Y,Altay H,Nalbantgil S,Temizhan A,YILMAZ M Akut Kalp Yetersizliğinde Taburculuk Öncesi ve Sonrası Hasta Yönetimi ve Tedavi Optimizasyonu. . 2022; 378 - 394. 10.5543/tkda.2022.22329 |
| Vancouver | Çavuşoğlu Y,Altay H,Nalbantgil S,Temizhan A,YILMAZ M Akut Kalp Yetersizliğinde Taburculuk Öncesi ve Sonrası Hasta Yönetimi ve Tedavi Optimizasyonu. . 2022; 378 - 394. 10.5543/tkda.2022.22329 |
| IEEE | Çavuşoğlu Y,Altay H,Nalbantgil S,Temizhan A,YILMAZ M "Akut Kalp Yetersizliğinde Taburculuk Öncesi ve Sonrası Hasta Yönetimi ve Tedavi Optimizasyonu." , ss.378 - 394, 2022. 10.5543/tkda.2022.22329 |
| ISNAD | Çavuşoğlu, Yüksel vd. "Akut Kalp Yetersizliğinde Taburculuk Öncesi ve Sonrası Hasta Yönetimi ve Tedavi Optimizasyonu". (2022), 378-394. https://doi.org/10.5543/tkda.2022.22329 |
| APA | Çavuşoğlu Y, Altay H, Nalbantgil S, Temizhan A, YILMAZ M (2022). Akut Kalp Yetersizliğinde Taburculuk Öncesi ve Sonrası Hasta Yönetimi ve Tedavi Optimizasyonu. Türk Kardiyoloji Derneği Arşivi, 50(5), 378 - 394. 10.5543/tkda.2022.22329 |
| Chicago | Çavuşoğlu Yüksel,Altay Hakan,Nalbantgil Sanem,Temizhan Ahmet,YILMAZ MEHMET BIRHAN Akut Kalp Yetersizliğinde Taburculuk Öncesi ve Sonrası Hasta Yönetimi ve Tedavi Optimizasyonu. Türk Kardiyoloji Derneği Arşivi 50, no.5 (2022): 378 - 394. 10.5543/tkda.2022.22329 |
| MLA | Çavuşoğlu Yüksel,Altay Hakan,Nalbantgil Sanem,Temizhan Ahmet,YILMAZ MEHMET BIRHAN Akut Kalp Yetersizliğinde Taburculuk Öncesi ve Sonrası Hasta Yönetimi ve Tedavi Optimizasyonu. Türk Kardiyoloji Derneği Arşivi, vol.50, no.5, 2022, ss.378 - 394. 10.5543/tkda.2022.22329 |
| AMA | Çavuşoğlu Y,Altay H,Nalbantgil S,Temizhan A,YILMAZ M Akut Kalp Yetersizliğinde Taburculuk Öncesi ve Sonrası Hasta Yönetimi ve Tedavi Optimizasyonu. Türk Kardiyoloji Derneği Arşivi. 2022; 50(5): 378 - 394. 10.5543/tkda.2022.22329 |
| Vancouver | Çavuşoğlu Y,Altay H,Nalbantgil S,Temizhan A,YILMAZ M Akut Kalp Yetersizliğinde Taburculuk Öncesi ve Sonrası Hasta Yönetimi ve Tedavi Optimizasyonu. Türk Kardiyoloji Derneği Arşivi. 2022; 50(5): 378 - 394. 10.5543/tkda.2022.22329 |
| IEEE | Çavuşoğlu Y,Altay H,Nalbantgil S,Temizhan A,YILMAZ M "Akut Kalp Yetersizliğinde Taburculuk Öncesi ve Sonrası Hasta Yönetimi ve Tedavi Optimizasyonu." Türk Kardiyoloji Derneği Arşivi, 50, ss.378 - 394, 2022. 10.5543/tkda.2022.22329 |
| ISNAD | Çavuşoğlu, Yüksel vd. "Akut Kalp Yetersizliğinde Taburculuk Öncesi ve Sonrası Hasta Yönetimi ve Tedavi Optimizasyonu". Türk Kardiyoloji Derneği Arşivi 50/5 (2022), 378-394. https://doi.org/10.5543/tkda.2022.22329 |
